/
CALC
$0.99+$0.17 (+20.97%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$12.9M
16M shares
52-week range
$0.46 – $7.20
8% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
216.57%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-5.34
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $175.0K | $303.0K | $395.0K | $519.0K | $0 | $0 | $0 | $46.0K |
| Gross profit | −$175.0K | −$303.0K | −$395.0K | −$519.0K | $0 | $0 | $0 | −$46.0K |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $23.0M | $30.6M | $21.0M | $18.9M | $8.3M | $15.9M | $14.5M | $15.2M |
| Operating income | −$28.6M | −$37.5M | −$29.8M | −$35.9M | −$14.2M | −$38.1M | −$24.2M | −$23.1M |
| EBITDA | −$28.2M | −$36.7M | −$27.1M | −$35.3M | −$7.6M | −$34.2M | −$13.6M | −$28.1M |
| Net income | −$28.4M | −$37.0M | −$27.5M | −$35.8M | −$7.8M | −$34.4M | −$13.7M | −$29.6M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -33.10 | -35.85 | -73.50 | -23.66 | -23.20 | -7.65 | -1.22 | -1.97 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $-0.62 | $-0.85–$-0.38 | 2 |
| 2027 | $7M | $-1.31 | $-2.12–$-0.51 | 2 |
| 2028 | $4M | $-1.23 | $-1.92–$-0.53 | 2 |
| 2029 | $15M | $-2.12 | $-2.12–$-2.12 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.00
Price
$0.99
Implied downside
-100%
Peer comparison
CalciMedica, Inc. Common Stock
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
www.calcimedica.com- Employees
- 16
- IPO / List date
- Sep 25, 2020
- HQ
- LA JOLLA, CA
Held by traders on TradeandTell
No one on the platform currently holds CALC.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 128,075 | $69.2K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2023-03-20 | 1-for-14reverse |
Recent trades on TradeandTell
No one on the platform has traded CALC yet.
